{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T20:24:27Z","timestamp":1773347067103,"version":"3.50.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vph.2023.107180","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T21:48:54Z","timestamp":1683841734000},"page":"107180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets"],"prefix":"10.1016","volume":"151","author":[{"given":"Charifa","family":"Awada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Boucherat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steeve","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Potus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0010","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00145608","article-title":"Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review","volume":"34","author":"Kovacs","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0015","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"25 Suppl","key":"10.1016\/j.vph.2023.107180_bb0020","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.vph.2023.107180_bb0025","first-page":"401","article-title":"Group 2 Pulmonary hypertension: pulmonary venous hypertension: epidemiology and pathophysiology","volume":"34","author":"Clark","year":"2016","journal-title":"Cardiol. Clin."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bph.15016","article-title":"Current and future treatments of pulmonary arterial hypertension","volume":"178","author":"Sommer","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.acvd.2017.01.010","article-title":"Pulmonary hypertension due to left heart disease","volume":"110","author":"Berthelot","year":"2017","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0040","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5114\/aoms.2017.68938","article-title":"Pulmonary hypertension in left heart disease","volume":"15","author":"Mehra","year":"2019","journal-title":"Arch. Med. Sci."},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00059-019-4831-6","article-title":"Pulmonary hypertension in HFpEF and HFrEF: pathophysiology, diagnosis, treatment approaches","volume":"44","author":"Rosenkranz","year":"2019","journal-title":"Herz"},{"issue":"10","key":"10.1016\/j.vph.2023.107180_bb0055","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1164\/rccm.201503-0529OC","article-title":"Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival","volume":"192","author":"Gerges","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.vph.2023.107180_bb0060","doi-asserted-by":"crossref","unstructured":"\u201cGlobal Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction.\u201d https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031608 (accessed Jan. 19, 2023).","DOI":"10.1161\/CIRCULATIONAHA.117.031608"},{"issue":"11","key":"10.1016\/j.vph.2023.107180_bb0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/clc.22579","article-title":"Combined post- and precapillary pulmonary hypertension in patients with heart failure","volume":"39","author":"Rezaee","year":"2016","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.vph.2023.107180_bb0070","doi-asserted-by":"crossref","unstructured":"\u201cElucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: A Call to Action: A Science Advisory from the American Heart Association | Circulation.\u201d https:\/\/doi.org\/10.1161\/CIR.0000000000001079 (accessed Jan. 19, 2023).","DOI":"10.1161\/CIR.0000000000001079"},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0075","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1056\/NEJMoa021650","article-title":"Signaling molecules in nonfamilial pulmonary hypertension","volume":"348","author":"Du","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.vph.2023.107180_bb0080","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020633","article-title":"Therapeutic challenges and emerging treatment targets for pulmonary hypertension in left heart disease","volume":"10","author":"Lteif","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/HYPERTENSIONAHA.117.08824","article-title":"models and molecular mechanisms of World Health Organization Group 2 to 4 pulmonary hypertension","volume":"71","author":"Xiong","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0090","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1183\/09031936.00043310","article-title":"Mast cells promote lung vascular remodelling in pulmonary hypertension","volume":"37","author":"Hoffmann","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0100","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0735-1097(99)00408-8","article-title":"Pulmonary hypertension and exercise intolerance in patients with heart failure","volume":"34","author":"Butler","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.vph.2023.107180_bb0105","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.jacc.2003.11.040","article-title":"Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry","volume":"43","author":"Klapholz","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jacc.2011.09.062","article-title":"Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy","volume":"59","author":"Schwartzenberg","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.amjcard.2010.02.039","article-title":"Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction","volume":"106","author":"Leung","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.vph.2023.107180_bb0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cardfail.2014.05.003","article-title":"Outcomes in World Health Organization Group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction\u2013induced pulmonary hypertension","volume":"20","author":"Salamon","year":"2014","journal-title":"J. Card. Fail."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14017431.2017.1311023","article-title":"Prevalence of heart failure in the elderly and future projections: the AGES-Reykjav\u00edk study","volume":"51","author":"Danielsen","year":"2017","journal-title":"Scand. Cardiovasc. J. SCJ"},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0135","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003973","article-title":"Increasing incidence and prevalence of World Health Organization Groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada","volume":"11","author":"Wijeratne","year":"2018","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21693\/1933-088X.15.1.26","article-title":"Pulmonary hypertension and palliative care: what, when, where, and why?","volume":"15","author":"Fenstad","year":"2016","journal-title":"Adv. Pulm. Hypertens."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0145","first-page":"572","article-title":"Pulmonary hypertension due to left heart disease\u2014a practical approach to diagnosis and management","volume":"37","author":"Lee","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.vph.2023.107180_bb0150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2261-13-52","article-title":"Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials","volume":"13","author":"Al-Gobari","year":"2013","journal-title":"BMC Cardiovasc. Disord."},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0155","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40256-017-0221-8","article-title":"The real role of \u03b2-blockers in daily cardiovascular therapy","volume":"17","author":"D\u00e9zsi","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs Drugs Devices Interv."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003703","article-title":"Use of \u03b2-blockers in pulmonary hypertension","volume":"10","author":"Perros","year":"2017","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0165","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10741-016-9566-3","article-title":"Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure","volume":"21","author":"Ameri","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.vph.2023.107180_bb0170","author":"University of Florida"},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0175","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacbts.2020.01.009","article-title":"Design of the \u03b23-adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial","volume":"5","author":"Garcia-Lunar","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00395-016-0567-0","article-title":"Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension","volume":"111","author":"Garc\u00eda-\u00c1lvarez","year":"2016","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.vph.2023.107180_bb0185","unstructured":"\u03b23 Adrenergic Stimulation of the Cardiac Na+-K+ Pump by Reversal of an Inhibitory Oxidative Modification | Circulation full\/10.1161\/CIRCULATIONAHA.110.964619 (accessed Feb. 02, 2023)."},{"issue":"7","key":"10.1016\/j.vph.2023.107180_bb0190","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009120","article-title":"Hemodynamic effects of cyclic guanosine monophosphate-dependent signaling through \u03b23 adrenoceptor stimulation in patients with advanced heart failure: a randomized invasive clinical trial","volume":"15","author":"Bundgaard","year":"2022","journal-title":"Circ. Heart Fail."},{"issue":"8","key":"10.1016\/j.vph.2023.107180_bb0200","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107180_bb0205","unstructured":"L. Mielniczuk, \u201cSpironolactone Therapy in Chronic Stable Right HF Trial,\u201d clinicaltrials.gov, Clinical trial registration NCT03344159, Jan. 2023. Accessed: Jan. 22, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03344159."},{"issue":"21","key":"10.1016\/j.vph.2023.107180_bb0210","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2023.107180_bb0215","doi-asserted-by":"crossref","unstructured":"\u201cEffects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus | Circulation.\u201d https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040057 (accessed Jan. 23, 2023).","DOI":"10.1161\/CIRCULATIONAHA.119.040057"},{"key":"10.1016\/j.vph.2023.107180_bb0220","doi-asserted-by":"crossref","unstructured":"\u201cEmpagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM.\u201d https:\/\/doi.org\/10.1056\/NEJMoa2107038 (accessed Jan. 23, 2023).","DOI":"10.1056\/NEJMoa2107038"},{"issue":"17","key":"10.1016\/j.vph.2023.107180_bb0225","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.vph.2023.107180_bb0230","doi-asserted-by":"crossref","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","article-title":"SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery","volume":"309","author":"Han","year":"2015","journal-title":"Am. J. Physiol. - Lung Cell. Mol. Physiol."},{"issue":"12","key":"10.1016\/j.vph.2023.107180_bb0235","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1053\/euhj.1999.1485","article-title":"Safety and effects of physical training in chronic heart failure. Results of the Chronic Heart Failure and Graded Exercise study (CHANGE)","volume":"20","author":"Wielenga","year":"1999","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejheart.2005.05.002","article-title":"The effect of physical training in chronic heart failure","volume":"8","author":"J\u00f3nsd\u00f3ttir","year":"2006","journal-title":"Eur. J. Heart Fail."},{"issue":"16","key":"10.1016\/j.vph.2023.107180_bb0245","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1177\/2047487318792315","article-title":"Best mode of inspiratory muscle training in heart failure patients: a systematic review and meta-analysis","volume":"25","author":"Sadek","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.vph.2023.107180_bb0250","year":"2022"},{"issue":"3","key":"10.1016\/j.vph.2023.107180_bb0255","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1010-7940(00)00345-6","article-title":"Mitral valve surgery in patients with severe left ventricular dysfunction","volume":"17","author":"Bishay","year":"2000","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0260","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/jpm12040603","article-title":"Severe aortic valve stenosis and pulmonary hypertension: a systematic review of non-invasive ways of risk stratification, especially in patients undergoing transcatheter aortic valve replacement","volume":"12","author":"Boxhammer","year":"2022","journal-title":"J. Pers. Med."},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0265","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ejcts.2004.01.052","article-title":"Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study","volume":"25","author":"Martin","year":"2004","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0270","first-page":"456","article-title":"Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension","volume":"51","author":"Haddad","year":"2005","journal-title":"ASAIO J. Am. Soc. Artif. Intern. Organs 1992"},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0275","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.hlc.2018.04.299","article-title":"Left ventricular assist devices in Pulmonary Hypertension Group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure","volume":"28","author":"Selim","year":"2019","journal-title":"Heart Lung Circ."},{"issue":"3","key":"10.1016\/j.vph.2023.107180_bb0280","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/HCO.0b013e3282f54fea","article-title":"Advances in the surgical treatment of heart failure","volume":"23","author":"Allen","year":"2008","journal-title":"Curr. Opin. Cardiol."},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0285","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1388-9842(03)00059-X","article-title":"Reversible pulmonary hypertension in heart transplant candidates--pretransplant evaluation and outcome after orthotopic heart transplantation","volume":"5","author":"Klotz","year":"2003","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21693\/1933-088X-17.1.15","article-title":"Palliative care and advance care planning in pulmonary hypertension","volume":"17","author":"Rhee","year":"2018","journal-title":"Adv. Pulm. Hypertens."},{"issue":"150","key":"10.1016\/j.vph.2023.107180_bb0295","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0069-2018","article-title":"Palliative care in pulmonary arterial hypertension: an underutilised treatment","volume":"27","author":"Khirfan","year":"2018","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0300","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12170-020-00663-3","article-title":"Management of pulmonary arterial hypertension","volume":"15","author":"Mayeux","year":"2021","journal-title":"Curr. Cardiovasc. Risk Rep."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s41030-019-00105-5","article-title":"Diagnosis and management of pulmonary hypertension in the modern era: insights from the 6th World Symposium","volume":"6","author":"Thomas","year":"2020","journal-title":"Pulm. Ther."},{"issue":"8977","key":"10.1016\/j.vph.2023.107180_bb0310","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","article-title":"Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure","volume":"346","author":"Kiowski","year":"1995","journal-title":"Lancet Lond. Engl."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0315","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamacardio.2016.0962","article-title":"Association of elevated plasma endothelin-1 levels with pulmonary hypertension, mortality, and heart failure in African American Individuals: the Jackson heart study","volume":"1","author":"Jankowich","year":"2016","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0320","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/oxfordjournals.eurheartj.a015228","article-title":"Prognostic value of plasma endothelin-1 in patients with chronic heart failure","volume":"18","author":"Pousset","year":"1997","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0325","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1388-9842(01)00210-0","article-title":"Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology \u2014 WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME","volume":"3","author":"Coletta","year":"2001","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0330","doi-asserted-by":"crossref","DOI":"10.1177\/2045893217745019","article-title":"The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension","volume":"8","author":"Meoli","year":"2018","journal-title":"Pulm. Circ."},{"issue":"9","key":"10.1016\/j.vph.2023.107180_bb0335","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0340","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.vph.2023.107180_bb0345","author":"Actelion"},{"issue":"21","key":"10.1016\/j.vph.2023.107180_bb0350","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"S\u00fctsch","year":"1998","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0355","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0360","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.vph.2023.107180_bb0365","author":"W. G. M.D"},{"issue":"10","key":"10.1016\/j.vph.2023.107180_bb0370","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.RES.83.10.969","article-title":"Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog","volume":"83","author":"Recchia","year":"1998","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2023.107180_bb0375","doi-asserted-by":"crossref","unstructured":"\u201cDecreased Activity of the l-Arginine\u2013Nitric Oxide Metabolic Pathway in Patients with Congestive Heart Failure | Circulation.\u201d https:\/\/doi.org\/10.1161\/01.CIR.99.16.2113 (accessed Jan. 23, 2023).","DOI":"10.1161\/01.CIR.99.16.2113"},{"key":"10.1016\/j.vph.2023.107180_bb0380","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.niox.2016.02.006","article-title":"Effect of asymmetric dimethylarginine (ADMA) on heart failure development","volume":"54","author":"Liu","year":"2016","journal-title":"Nitric Oxide Biol. Chem. Off. J. Nitric Oxide Soc."},{"key":"10.1016\/j.vph.2023.107180_bb0385","doi-asserted-by":"crossref","unstructured":"\u201cFunctional Consequences of Endothelial Nitric Oxide Synthase Uncoupling in Congestive Cardiac Failure.\u201d https:\/\/doi.org\/10.1161\/01.CIR.0000066283.13253.78 (accessed Feb. 02, 2023).","DOI":"10.1161\/01.CIR.0000066283.13253.78"},{"issue":"3","key":"10.1016\/j.vph.2023.107180_bb0390","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/01.CIR.100.3.216","article-title":"Increased superoxide in heart failure: a biochemical baroreflex gone awry","volume":"100","author":"M\u00fcnzel","year":"1999","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0395","doi-asserted-by":"crossref","DOI":"10.1038\/nrd2466","article-title":"The nitrate\u2013nitrite\u2013nitric oxide pathway in physiology and therapeutics","volume":"7","author":"Lundberg","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.vph.2023.107180_bb0400","doi-asserted-by":"crossref","unstructured":"\u201cIsosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction | NEJM.\u201d https:\/\/doi.org\/10.1056\/nejmoa1510774 (accessed Jan. 23, 2023).","DOI":"10.1056\/NEJMoa1510774"},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0405","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jchf.2015.12.013","article-title":"One week of daily dosing with beetroot juice improves submaximal endurance and blood pressure in older patients with heart failure and preserved ejection fraction","volume":"4","author":"Eggebeen","year":"2016","journal-title":"JACC Heart Fail."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0410","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10557-020-06980-4","article-title":"Efficacy and safety of inorganic nitrate versus placebo treatment in heart failure with preserved ejection fraction","volume":"34","author":"Gui","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"17","key":"10.1016\/j.vph.2023.107180_bb0415","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2018.14852","article-title":"Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: The INDIE-HFpEF randomized clinical trial","volume":"320","author":"Borlaug","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0420","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0425","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.vph.2023.107180_bb0430","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.115.018935","article-title":"SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction","volume":"133","author":"Lai","year":"2016","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.vph.2023.107180_bb0435","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89620","article-title":"Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction","volume":"1","author":"Simon","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.vph.2023.107180_bb0440","unstructured":"M. Risbano, \u201cPhase II Clinical Investigation of Oral Nitrite in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF),\u201d clinicaltrials.gov, Clinical trial registration NCT03015402, Oct. 2022. Accessed: Jan. 22, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03015402."},{"key":"10.1016\/j.vph.2023.107180_bb0445","unstructured":"A. Morris, \u201cAn Open Label Study of Oral Nitrate in Adults with Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) and Normal Healthy Adults,\u201d clinicaltrials.gov, Clinical trial registration NCT02980068, Mar. 2022. Accessed: Jan. 22, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02980068."},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0450","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0005-2728(99)00024-9","article-title":"Guanylate cyclase and the \u00b7NO\/cGMP signaling pathway","volume":"1411","author":"Denninger","year":"1999","journal-title":"Biochim. Biophys. Acta BBA - Bioenerg."},{"issue":"15","key":"10.1016\/j.vph.2023.107180_bb0455","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/01.CIR.0000144469.01521.8A","article-title":"Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs","volume":"110","author":"Evgenov","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0460","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107180_bb0465","author":"Bayer"},{"key":"10.1016\/j.vph.2023.107180_bb0470","author":"Merck Sharp & Dohme LLC"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2023.107180_bb0475","doi-asserted-by":"crossref","first-page":"P51","DOI":"10.1186\/1471-2210-9-S1-P51","article-title":"Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure","volume":"9","author":"Mitrovic","year":"2009","journal-title":"BMC Pharmacol."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0485","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0490","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1183\/09031936.00124007","article-title":"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension","volume":"32","author":"Wilkins","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0495","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/ciia.2006.1.4.403","article-title":"Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence","volume":"1","author":"Hatzimouratidis","year":"2006","journal-title":"Clin. Interv. Aging"},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0500","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/vhrm.2006.2.4.411","article-title":"Sildenafil in the treatment of pulmonary hypertension","volume":"2","author":"Barnett","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0505","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107180_bb0510","doi-asserted-by":"crossref","unstructured":"\u201cSildenafil Improves Exercise Capacity and Quality of Life in Patients with Systolic Heart Failure and Secondary Pulmonary Hypertension | Circulation.\u201d : https:\/\/doi.org\/10.1161\/circulationaha.107.716373 (accessed Jan. 23, 2023).","DOI":"10.1161\/CIRCULATIONAHA.107.716373"},{"key":"10.1016\/j.vph.2023.107180_bb0515","author":"Hospital General Universitario Gregorio Mara\u00f1on"},{"issue":"38","key":"10.1016\/j.vph.2023.107180_bb0520","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2023.107180_bb0525","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","article-title":"Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension","volume":"283","author":"Kramer","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0530","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0008-6363(02)00841-6","article-title":"[Na+]i handling in the failing human heart","volume":"57","author":"Pieske","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.vph.2023.107180_bb0535","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","article-title":"Role of ranolazine in angina, heart failure, arrhythmias, and diabetes","volume":"133","author":"Sossalla","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0540","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2008.03.006","article-title":"Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts \u2014 role of late sodium current and intracellular ion accumulation","volume":"45","author":"Sossalla","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0545","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/sj.bjp.0706713","article-title":"Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?","volume":"148","author":"Makielski","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0550","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1054\/jcaf.2002.129232","article-title":"Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure","volume":"8","author":"Sabbah","year":"2002","journal-title":"J. Card. Fail."},{"issue":"8","key":"10.1016\/j.vph.2023.107180_bb0560","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/cvr\/28.8.1231","article-title":"Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart","volume":"28","author":"Gralinski","year":"1994","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0565","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00877121","article-title":"Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease","volume":"8","author":"Hayashida","year":"1994","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"12","key":"10.1016\/j.vph.2023.107180_bb0570","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1540-8167.2008.01246.x","article-title":"Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome","volume":"19","author":"Moss","year":"2008","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.vph.2023.107180_bb0575","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ijcard.2016.08.330","article-title":"Ranolazine as a novel therapy for pulmonary arterial hypertension","volume":"223","author":"Gong","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.vph.2023.107180_bb0580","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.healun.2016.07.015","article-title":"Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: a pilot study","volume":"35","author":"Finch","year":"2016","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"issue":"10","key":"10.1016\/j.vph.2023.107180_bb0585","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/CIRCULATIONAHA.106.668640","article-title":"Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships","volume":"115","author":"Givertz","year":"2007","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.vph.2023.107180_bb0590","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2006.06.052","article-title":"Effects of levosimendan on right ventricular function in patients with advanced heart failure","volume":"98","author":"Parissis","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0595","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00059-008-3051-2","article-title":"Safety and effectiveness of levosimendan in patients with predominant right heart failure","volume":"33","author":"Poelzl","year":"2008","journal-title":"Herz"},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0600","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/crj.12699","article-title":"Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension","volume":"12","author":"Jiang","year":"2018","journal-title":"Clin. Respir. J."},{"issue":"3","key":"10.1016\/j.vph.2023.107180_bb0605","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018790905","article-title":"Levosimendan in pulmonary hypertension and right heart failure","volume":"8","author":"Hansen","year":"2018","journal-title":"Pulm. Circ."},{"issue":"8","key":"10.1016\/j.vph.2023.107180_bb0610","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944717711379","article-title":"Metabolic syndrome: pathophysiology, management, and modulation by natural compounds","volume":"11","author":"Rochlani","year":"2017","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0615","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1378\/chest.08-2008","article-title":"Association of the metabolic syndrome with pulmonary venous hypertension","volume":"136","author":"Robbins","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.vph.2023.107180_bb0620","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/crj.12406","article-title":"Prevalence of metabolic syndrome in patients with pulmonary hypertension","volume":"11","author":"Ussavarungsi","year":"2017","journal-title":"Clin. Respir. J."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0625","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2023.107180_bb0630","author":"University of California, San Francisco"},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0635","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/CIRCRESAHA.115.303404","article-title":"The genetics of pulmonary arterial hypertension","volume":"115","author":"Austin","year":"2014","journal-title":"Circ. Res."},{"issue":"23","key":"10.1016\/j.vph.2023.107180_bb0640","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2016.09.942","article-title":"Clinical and biological insights into combined post-capillary and pre-capillary pulmonary hypertension","volume":"68","author":"Assad","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.vph.2023.107180_bb0645","article-title":"Pulmonary arterial hypertension-associated genetic variants in combined post-capillary and pre-capillary pulmonary hypertension: a case report","volume":"11","author":"Chomette","year":"2021","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.vph.2023.107180_bb0650","doi-asserted-by":"crossref","unstructured":"\u201cSotatercept for the Treatment of Pulmonary Arterial Hypertension | NEJM.\u201d https:\/\/doi.org\/10.1056\/NEJMoa2024277 (accessed Mar. 19, 2022).","DOI":"10.1056\/NEJMoa2024277"},{"key":"10.1016\/j.vph.2023.107180_bb0655","author":"Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)"},{"key":"10.1016\/j.vph.2023.107180_bb0660","unstructured":"\u201cPADN-CFDA: Pulmonary Artery Denervation Shows Promise for Treating PAH,\u201d American College of Cardiology. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2022\/09\/16\/18\/24\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2022%2f09%2f16%2f18%2f24%2fsun-1215pm-padn-cfda-tct-2022 (accessed Feb. 02, 2023)."},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0665","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018816297","article-title":"Pulmonary artery denervation improves hemodynamics and cardiac function in pulmonary hypertension secondary to heart failure","volume":"9","author":"Zhang","year":"2019","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.vph.2023.107180_bb0670","doi-asserted-by":"crossref","unstructured":"\u201cHemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients with Pulmonary Arterial Hypertension of Different Causes | Circulation: Cardiovascular Interventions.\u201d https:\/\/doi.org\/10.1161\/circinterventions.115.002837 (accessed Jan. 23, 2023).","DOI":"10.1161\/CIRCINTERVENTIONS.115.002837"},{"issue":"3","key":"10.1016\/j.vph.2023.107180_bb0675","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2018.09.021","article-title":"Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study","volume":"12","author":"Zhang","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.vph.2023.107180_bb0680","author":"SoniVie Inc."},{"issue":"5","key":"10.1016\/j.vph.2023.107180_bb0685","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jtcvs.2017.06.053","article-title":"Pulmonary hypertension due to left heart disease causes intrapulmonary venous arterialization in rats","volume":"154","author":"Fujimoto","year":"2017","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"4","key":"10.1016\/j.vph.2023.107180_bb0690","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1165\/rcmb.2016-0177OC","article-title":"Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction","volume":"56","author":"Meng","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.vph.2023.107180_bb0695","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1378\/chest.12-2114","article-title":"WHO\u2019s in second?","volume":"144","author":"Hansdottir","year":"2013","journal-title":"Chest"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912300040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912300040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:22:07Z","timestamp":1761528127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153718912300040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":135,"alternative-id":["S153718912300040X"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2023.107180","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2023.107180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107180"}}